New Key Statistics Module, Z-Score and F-Score
TSX:HLS Key Ratios
| Market Cap C$ M | 111.28 |
| Enterprise Value C$ M | 183.69 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 1.04 |
| Price/Sales | 1.45 |
| Price/Free Cash Flow | 9.70 |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) C$ M | 77.00 |
| EPS (TTM) C$ | -0.94 |
| Beneish M-Score | -3.2 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -10.00 |
| y-y EBITDA Growth Rate % | 34.00 |
| EV-to-EBIT | -18.00 |
| EV-to-EBITDA | 8.07 |
| PEG | -- |
| Shares Outstanding M | 31.79 |
| Net Margin (%) | -38.71 |
| Operating Margin % | -8.88 |
| Pre-tax Margin (%) | -31.49 |
| Quick Ratio | 1.24 |
| Current Ratio | 1.56 |
| ROA % (ttm) | -11.19 |
| ROE % (ttm) | -24.47 |
| ROIC % (ttm) | -3.76 |
| Dividend Yield % | -- |
| Altman Z-Score | -0.74 |
TSX:HLS Number of Guru Trades
TSX:HLS Volume of Guru Trades
Gurus Latest Trades with TSX:HLS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
TSX:HLS is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
HLS Therapeutics Inc Insider Transactions
No Available Data
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers